Goserelin and bicalutamide treatments alter the expression of microRNAs in prostate
Ontology highlight
ABSTRACT: 30 patients were randomized equally into three groups: no treatment, bicalutamide (antiandrogen) 150 mg daily, and goserelin (GnRH agonist) 3.6 mg every 4 weeks. Following the neoadjuvant treatment for 12 weeks, patients underwent radical prostatectomy. Freshly frozen specimens were collected for expression profiling by human Agilent miRNA V2 microarray chips. Each array contained probe sets for 723 human miRNAs according to Sanger miRBase v 10.1
ORGANISM(S): Homo sapiens
SUBMITTER: Saara Lehmusvaara
PROVIDER: E-MEXP-3530 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA